A PROSPECTIVE, RANDOMIZED AND OPEN LABEL STUDY TO COMPARE EFFICACY AND SAFETY OF TOPICAL GLUTATHIONE (2%) WITH TOPICAL TRANEXAMIC ACID (3%) IN ADULT MELASMA PATIENTS

A PROSPECTIVE, RANDOMIZED AND OPEN LABEL STUDY TO COMPARE EFFICACY AND SAFETY OF TOPICAL GLUTATHIONE (2%) WITH TOPICAL TRANEXAMIC ACID (3%) IN ADULT MELASMA PATIENTS - TGTTAS

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000050940

Enrollment

Registered

2023-05-04

Start date

2022-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MELASMA

Interventions

Topical Glutathione (2%), each time - amount sufficient for thin uniform film over face, BD (Twice daily - morning and evening) Topical tranexamic acid (3%), each time - amount sufficient for thin uni

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Melasma patients diagnosed clinically Study subjects between eighteen to sixty years of age, irrespective of sex, socio-economic status and duration of lesions

Exclusion criteria

Exclusion criteria: Patients refusing to give written informed consent Hypersensitivity to test drugs Pregnancy and lactation Any major comorbidities Hormonal medication 3 months prior to study

Design outcomes

Primary

Measure	Time frame
Evaluation of efficacy of topical glutathione (2%) in comparison to topical tranexamic acid (3%) through evaluation by Modified Melasma Area Severity Index at baseline, 30, 60 and 90 days of study (mMASI) and Physician Global Assessment (PGA) scores at 30, 60 and 90 days of study	—

Secondary

Measure	Time frame
Evaluation of safety by documenting proportion of adverse effects in each group at 30, 60 and 90 days of study Evaluation of quality of life by Melasma Quality of Life Index (MELASQOL) at baseline and 90 days of study	—

Countries

Asia(except Japan)

Contacts

Public ContactDR SAURABH BIJALWAN

GOVERNMENT MEDICAL COLLEGE AMRITSAR PHARMACOLOGY

SOPHSHAN93@GMAIL.COM+917895168233

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026